FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME Board of Directors Pierre Legault, MBA - Chairman of the Board Khoso Baluch Pascale Boissel, HEC Masters, CPA Janice Bourque Thierry Hercend, MD, PhD Richard Kender, BS, MBA Thomas Kuhn, Pharm D, MBA Olivier Martinez, PhD, MBA Bruno Montanari, Pharm D Raphaël Wisniewski Pierre Legault, MBA Chairman of the Board Pierre Legault, MBA, CA, CPA, is Chairman of the Board and has served as a director of Poxel since March 2016. Mr. Legault also serves as a member of Tobira Therapeutics (Chairman of audit committee), Iroko Pharmaceuticals and NephroGenex Boards. He previously served as Board member, Chairman and Chair of audit committee of Forest Laboratories, NPS Pharmaceuticals, Regado Pharmaceuticals, OSI Investment Holdings GMBH, Cyclacel Pharmaceuticals, Inc., The Jean Coutu Group (PJC) Inc. (and others). Mr. Legault served as chief executive officer, president and chief financial officer of several public companies including Eckerd Pharmacies, NephroGenex, OSI Pharmaceuticals, Rite Aid (and others), as well as chief executive officer of Prosidion, Ltd., a mid-size U.K. biotechnology firm. Mr. Legault also held several senior positions with Sanofi-Aventis and predecessor companies, including president of worldwide dermatology operations. He studied at McGill University, University of Montreal (HEC) and the Harvard Business School, and holds a Six Sigma Green Belt, a BAA, MBA, CA and CPA diploma. Khoso Baluch SVP & President Europe Region at UCB, Independent administrator Khoso Baluch is Senior Vice President & President European Region at UCB, the global biopharmaceutical company. Prior to joining UCB, Khoso worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Khoso was appointed Vice President of U.S. Diabetes and Family Health Business unit during his tenure at Lilly. He served as a Board Member of the Juvenile Diabetes Research Foundation, Indiana Chapter, and was Chair of the nomination committee. He also served at the American Diabetes Association National Industry Advisory Board. Khoso is also a member of the World Federation of Advertisers (WFA) Executive Committee. Pascale Boissel, HEC Paris, Master in Management, Certified Public Accountant Deputy CEO and Head of Finance & Administration BIOASTER, Independent Administrator Pascale Boissel is Deputy CEO and Head of Finance & Administration of the Technology Research Institute BIOASTER, an independent non-profit organization developing collaborative research programs in the fields of infectious disease and microbiology, which was created in the context of the governmental program “Investments for the Future”. Pascale started her career in auditing and corporate finance consultancy at Price Waterhouse Coopers. Following her time there, she supported publicly listed groups with broad international exposure, mainly in the Danone and Lafarge Groups, where she focused on managing teams and projects in reporting process improvement, business control and external development project evaluation. With dedicated knowhow in improving processes and projects for innovative organizations and reporting, Pascale has solid experience in international accounting and internal auditing standards. In 2009 she joined the biotech company Ipsogen as Chief Financial Officer, where she contributed to the reorganization of the company’s US business, supported the company in raising money through an increase in capital and also actively participated in Ipsogen’s acquisition by the Qiagen Group in 2011. Janice Bourque Managing Director of Life Sciences for Hercules Technology Growth Capital Janice Bourque is Managing Director of Life Sciences for Hercules Technology Growth Capital, a premier specialty finance company providing debt and equity to venture capital and private equity backed, and small cap public life science companies at all stages of development with $5.5 billion committed to over 325 life science, technology and sustainable and renewable technology companies. Previously, Ms. Bourque provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners for innovative healthcare investments for emerging and developing countries and was Senior Vice President, Group Head-Life Sciences for Comerica Bank. Ms. Bourque was President/CEO of the Massachusetts Biotechnology Council (MBC) which was at the forefront of the biotechnology revolution as the first biotechnology association in the world. Ms. Bourque is on several boards: Poxel Inc, The Village Bank, Commodore Builders, Forsyth Leadership Council, Emeritus Director of the MIT Koch Institute for Integrative Cancer Research Springboard Enterprises Life Science Council and is a member of the Women’s Forum. Ms. Bourque received her MBA degree in finance and accounting and her BS degree in veterinary science from the University of New Hampshire. Thierry Hercend, MD, PhD Venture Partner at EdRIP Thierry Hercend has over 30 years' experience in both academia and the pharmaceutical industry, in various therapeutic areas including oncology and inflammatory diseases. Since 2006, he has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe at Vertex Pharmaceuticals. Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and held various executive R&D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Hemato-Immunology Unit of the Gustave Roussy Cancer Institute, Villejuif, France; Director of Inserm Unit U333 dedicated to tumor immunology; and Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, autoimmune diseases and transplantation. Richard Kender, BS, MBA Formerly Senior Vice-President Business Development and Licensing, Merck and Co. Inc., Independent Administrator Richard Kender spent his entire career at Merck & Co., Inc. He started in accounting and finance roles of increasing responsibility and moved into corporate development in 1994. Mr. Kender was promoted to Vice President of Corporate Development in 1996 and in 2000, his responsibilities expanded to include Corporate Licensing and Worldwide Business Development, where he managed a department of approximately 70 people responsible for Merck’s M&A, Licensing, Financial Evaluation and Analysis and Global Competitive Intelligence. His numerous achievements include leading a multidivisional team to create the Joint Venture Merial Animal Health with Sanofi-Aventis, the acquisition of 49% of shares of Banyu Pharmaceuticals in Japan, the spin-off and IPO of Medco and, most notably, in 2008, Mr. Kender played a key role in the $41 billion Schering Plough acquisition. Mr. Kender retired from Merck in September 2013. He holds a BS in Accounting from Villanova University and an MBA from Fairleigh Dickinson University. Thomas Kuhn, Pharm D, MBA Chief Executive Officer of Poxel Thomas Kuhn joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes. Between 2004 and 2007 he directed global R&D projects, with two products in Phase 2 clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, Thomas was involved in refining Merck Serono's strategy. With the decision to divest from diabetes as an integrated therapeutic area, Thomas drove the project to relocate the diabetes assets, leading to the establishment of Poxel. Thomas received a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge University (UK). Olivier Martinez, PhD, MBA Investment Manager, Life Science team, CDC Entreprises Olivier Martinez joined Bioam Gestion in 2000 as an Associate and became Investment Manager and member of the executive board in 2004. Following the integration of Bioam Gestion into CDC Entreprises in July 2010, he is now in charge of managing investments of the InnoBio and Bioam funds. He currently serves on the boards of Cytheris, Adocia, Fab Pharma and Genticel. Prior to joining Bioam Gestion, Dr. Martinez spent two years working on healthcare projects in the Life Science Group of Gemini Consulting. From 1992 to 1997, he pursued his doctoral studies in cell biology at the Pasteur and Curie Institutes in Paris, followed by management training. He is an alumnus of the Ecole Normale Supérieure and holds a PhD in cell biology from the University of Paris XI and a diploma from the Collège des Ingénieurs. Bruno Montanari, Pharm D, HEC Masters Partner at Omnes Capital Bruno Montanari joined Omnes Capital VC team in 2010 after serving as a Principal at Atlas Venture and as Investment Director at CDP Capital Technology Ventures. Dr. Montanari began his career in 1999 in London with Deutsche Bank and later Merrill Lynch as a member of the Investment Banking teams covering the European pharmaceutical and biotech sectors. Mr. Montanari holds a PharmD (Paris V) and a Masters from HEC (Paris). Raphaël Wisniewski Investment Director at EdRIP Raphaël Wisniewski is investment director at Edmond de Rothschild Investment Partners (EdRIP) in the life sciences venture group. He sits on the board of several European life sciences companies on behalf of EdRIP. Prior to joining EdRIP in 2001, Mr. Wisniewski spent several years in London working for the hospital group General Healthcare Group and in the corporate finance practices of Salomon Smith Barney and Goldman Sachs. © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact